OSE Immunotherapeutics announces that it has received non-dilutive funding of 8.4 million euros under the i-Démo call for projects of the France 2030 plan, operated by Bpifrance on behalf of the.
OSE Immunotherapeutics Receives €8 4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi in Lung Cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE.
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.